Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07311694) titled 'A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Condition:
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Intervention:
Drug: HRS-4357 injection
Drug: Enzalutamide
Recruitment Status: Not recruiting
Phase: Phase 3
Date of Fi...